Xbrane Biopharma AB Ratios and Metrics

Market cap in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Feb '26 Feb 4, 2026	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Market Capitalization	213	246	297	2,258	2,624	1,661
Market Cap Growth	-16.21%	-17.28%	-86.83%	-13.94%	58.03%	211.34%
Enterprise Value	119	386	371	2,133	2,285	1,544
Last Close Price	10.32	20.10	1250.00	10262.50	13100.00	9350.00
Forward PE	-	18.40	-	-	-	-
PS Ratio	0.82	1.24	1.25	39.19	245.04	-
PB Ratio	0.36	1.18	1.74	5.32	6.08	6.44
P/TBV Ratio	0.36	1.18	1.74	5.32	6.08	8.33
EV/Sales Ratio	0.46	1.94	1.56	37.03	213.37	-
EV/FCF Ratio	-0.60	-	-	-	-	-
Debt / Equity Ratio	-	0.92	1.35	0.09	0.10	0.02
Asset Turnover	0.34	0.27	0.36	0.08	0.02	-
Inventory Turnover	0.29	0.10	2.59	-	-	-
Quick Ratio	0.90	0.40	0.42	1.02	1.84	1.68
Current Ratio	3.47	1.13	1.41	2.17	2.55	1.98
Return on Equity (ROE)	-36.66%	-139.53%	-108.02%	-39.34%	-53.15%	-104.60%
Return on Assets (ROA)	-8.36%	-16.97%	-27.60%	-13.84%	-19.14%	-33.74%
Return on Capital Employed (ROCE)	-17.60%	-66.70%	-90.80%	-33.60%	-37.60%	-78.80%
Earnings Yield	47.25%	-108.25%	-130.56%	-7.64%	-7.18%	-13.61%
FCF Yield	-93.63%	-54.58%	-139.07%	-9.10%	-9.42%	-14.59%
Buyback Yield / Dilution	-171.10%	-4184.97%	-12.26%	-8.38%	-30.25%	-61.86%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.